ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,910Medicare Part D Prescriptions Filled, Including Refills

Rank: 170 out of 1111

$595K Total Retail Price of All Prescriptions

Rank: 151 out of 1111

332 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
67% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oklahoma
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 332 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

25% of this provider’s 332 patients filled at least one prescription for a schedule three drug, compared to an average of 18%.

Risky Drugs to Seniors

0% of this provider’s 8,999 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oklahoma
LEVOTHYROXINE SODIUM 445 442 1 3
LISINOPRIL 405 371 2 2
FUROSEMIDE 320 288 3 6
HYDROCODONE-ACETAMINOPHEN 289 241 S3 4 1
OMEPRAZOLE 287 274 5 4
POTASSIUM CHLORIDE 237 211 6 9
SERTRALINE HCL 220 208 7 24
METOPROLOL TARTRATE 212 199 8 12
AMLODIPINE BESYLATE 203 188 9 7
WARFARIN SODIUM 192 191 10 19
SIMVASTATIN 178 174 11 5
HYDROCHLOROTHIAZIDE 158 152 12 11
NAMENDA 153 153 13 31
PRAVASTATIN SODIUM 149 136 14 17
RANITIDINE HCL 146 125 15 29
MIRTAZAPINE 142 136 16 52
GABAPENTIN 131 128 17 10
CITALOPRAM HBR 130 118 18 14
KLOR-CON M20 123 123 19 79
DONEPEZIL HCL 122 121 20 25
METFORMIN HCL 121 106 21 8
TRAMADOL HCL 107 103 22 13
ALBUTEROL SULFATE 92 51 23 136
CLOPIDOGREL 89 71 24 30
LANTUS 87 83 25 46
CYMBALTA 86 77 26 40
ZOLPIDEM TARTRATE 85 84 27 16
FLUTICASONE PROPIONATE 83 76 28 27
CARVEDILOL 83 73 28 21
FAMOTIDINE 79 67 30 77
METOPROLOL SUCCINATE 74 74 31 20
NOVOLOG 73 60 32 104
GLIPIZIDE 68 63 33 57
BETAMETHASONE VALERATE 67 64 34 327
LOVASTATIN 65 65 35 41
ATORVASTATIN CALCIUM 60 52 36 15
LOSARTAN POTASSIUM 59 59 37 34
SPIRIVA 58 58 38 53
TAMSULOSIN HCL 58 57 38 28
OLANZAPINE 57 57 40 117
POLYETHYLENE GLYCOL 3350 57 49 40 45
LACTULOSE 56 56 42 166
TRAVATAN Z 54 54 43 183
QUETIAPINE FUMARATE 53 53 44 76
SULFAMETHOXAZOLE-TRIMETHOPRIM 53 44 44 71
LISINOPRIL-HYDROCHLOROTHIAZIDE 52 49 46 23
ADVAIR DISKUS 52 52 46 43
ALLOPURINOL 51 39 48 36
ENALAPRIL MALEATE 51 51 48 56
ATENOLOL 51 51 48 22
ROPINIROLE HCL 50 45 51 68
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 3, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.